



NEWS RELEASE

February 28, 2020

TMS Co., Ltd.

### **TMS Co., Ltd. Successfully Closes a Finance Round**

TMS Co., Ltd. (Fuchu-shi, Tokyo, Japan) announces that the company has closed a finance round by issuing D-2 preferred stocks on February 27, 2020. The total committed capital amounts to 1.59 billion JPY (approximately 14.7million US dollars), including Series D-1 convertible bond raised in September 2019. The company expects that the final amount of this round will further be increased.

The raised capital will be invested in ongoing Phase IIa trial of TMS-007 and acceleration of other pipeline developments. TMS Co., Ltd. has partnered with Biogen MA, Inc. for development of TMS-007 since June 2018.

#### About TMS Co., Ltd.

TMS Co., Ltd. is a privately-held, clinical stage biopharmaceutical company based in Fuchu-shi, Tokyo. The company was founded in 2005 to develop therapeutics based on novel discoveries to modulate fibrinolytic system, identified by a team of scientists at Tokyo University of Agriculture and Technology (TUAT), led by Dr. Keiji Hasumi, Professor of the university and Chief Scientist of the company. The company conducts several research and developments for drug candidates including TMS-007 for acute ischemic stroke.

#### About TMS-007

TMS-007 is one of the novel SMTP compounds produced by *Stachybotrys Microspora*, a kind of mold and thought to have two different actions: the action of enhancing the thrombus removal action and the action of suppressing inflammation. This unique mechanism of action makes it a promising drug candidate for acute ischemic stroke and is expected to significantly expand the therapeutic time window, which is limited to 4.5 hours from onset.

Contacts Corporate Department 042-306-5078
--